课题基金 / 基金详情

Core--Real-time quantitative PCR facility

Core--Real-time quantitative PCR facility
核心--实时定量PCR设备
批准号:
6442594
负责人:
Dao Pan
金额:
$10.62万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-01-01 至 2001-12-31

项目摘要

项目成果

Dao Pan的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The purpose of the Real-Time Quantitative PCR Core is to assist investigators in evaluating gene transfer efficiency and transgenic expression in target ells for projects in the Gene Therapy for Metabolic Disorders program. As initially demonstrated by the current gene therapy clinical trial ("Lymphocyte gene therapy for Hunter syndrome), this technique fills a very significant scientific need to accurately quantitate the presence of a gene, and to measure its expression by reverse transcriptase-PCR (RT-PCR) with a high level of sensitivity and reproducibility. This core will assist investigators in designing assay systems (paired oligonucleotide primers and an internal fluorescent TaqMan probe), as well as accomplish the actual assays of research specimens. The availability of a core facility accomplishing assays for common biologic systems (e.g., gene and gene-products of OTC and MPS VII mouse models) eliminates redundancy and provides a greater level of quality assurance. The new, quantitative technology also provides sensitive methods for "safety assays" (e.g., for lentiviral vector RCR) that are much faster, reliable and inexpensive that existing culture techniques. The techniques also provides a method for quantitating gene products (RT-PCR) for which there are no existing assays, or for DNA sequences that do not yield a translational or transcriptional end product (as might be needed for transposon vectors).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Advancing CNS drug delivery via epigenetic modulation
Manipulation of microRNA for CNS delivery: implication to treatment of neurological LSD
Gaucher disease:Treatment of neurodegenerative disease
Gaucher disease:Treatment of neurodegenerative disease